Why Jean-Pierre Conte Chose UCSF for a Parkinson’s Research Gift

Donors weighing a major medical gift face a basic question: where will the money do the most good? For Jean-Pierre Conte, the answer pointed to the University of California, San Francisco. The choice was rooted in both reputation and personal history.

Conte, the founder and managing partner of the family office Lupine Crest Capital, gave UCSF $5 million through his family foundation in November 2024 to endow two professorships in neurology focused on Parkinson’s disease.

A Leading Research Institution

UCSF’s standing in medical research weighed on the choice. Conte pointed to the department’s leadership when he explained the gift. “Andy is such a great ambassador for UCSF,” he said of S. Andrew Josephson, the neurology chair who oversaw the professorships.

The university ranks among the country’s foremost centers for brain research, with clinicians who both treat patients and study disease. That combination appealed to Conte, who wanted his support to reach scientists working on real treatments for Parkinson’s and related conditions.

Honoring a Father’s Memory

The decision was personal, too. Conte’s father, Pierre, had Parkinson’s and was cared for by UCSF physicians, an experience that drew his son toward the disease and the institution alike. The gift carries that history in its purpose.

Endowing professorships, rather than funding a one-time study, matched the weight of that motivation. Conte chose a form of support that will continue for years, keeping his father’s memory tied to progress against a disease that still has no cure.

Matching the Gift to the Mission

Reputation and personal history pulled in the same direction. A hospital his family trusted was also a top destination for the research he wanted to fund, so the choice satisfied both the head and the heart. He didn’t have to weigh sentiment against results, because UCSF offered both.

That fit shaped the size and the structure of the commitment. Jean-Pierre Conte put lasting money behind an institution he already knew could use it well, confident the support would reach the scientists best placed to make progress. A gift that large, aimed at a place he trusted, had a strong chance of doing real good against Parkinson’s. He weighed the institution and the mechanism before committing, much as he once sized up a company and its team. A trusted hospital and an enduring structure, put together, gave the money its best chance to matter for years to come. He gave with exactly that long horizon in mind.